Share Name Share Symbol Market Type Share ISIN Share Description
Oxford Biomedica Plc LSE:OXB London Ordinary Share GB00BDFBVT43 ORD 50P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -11.00 -1.99% 543.00 543.00 547.00 552.00 543.00 552.00 28,247 13:37:55
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 66.8 5.0 11.6 46.9 417

Oxford Biomedica PLC Director Dealings / Market Share Purchase

13/09/2019 10:53am

UK Regulatory (RNS & others)


Oxford Biomedica (LSE:OXB)
Historical Stock Chart

2 Months : From Aug 2019 to Oct 2019

Click Here for more Oxford Biomedica Charts.

TIDMOXB

RNS Number : 2933M

Oxford Biomedica PLC

13 September 2019

Director Dealings / Market Share Purchase

Oxford, UK - 13 September 2019: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, today announces that Vulpes Testudo Fund, a person closely associated with Martin Diggle, Non-Executive Director, has purchased 17,953 ordinary shares of 50p each ("Ordinary Shares") in the Company on 12 September 2019 on the London Stock Exchange at a price of 576.8p per share. Following this purchase Vulpes Testudo/Vulpes Life Sciences Fund holds 11,658,640 ordinary shares representing 15.2% of the Company.

The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail of the number of Ordinary Shares purchased.

 
 1.   Details of the person discharging material responsibilities/person 
       closely associated 
 a.   Name                                         Vulpes Testudo Fund 
 2.   Reason for the notification 
 a.   Position/status                              Person closely associated with Martin 
                                                    Diggle, Non-Executive Director 
 b.   Initial notification                         Initial notification 
       /amendment 
3.    Details of the issuer, emission allowance, market 
       participant, auction platform, auctioneer or auction 
       monitor 
 a.   Name                                         Oxford Biomedica plc 
 b.   Legal Entity Identifier                      213800S1GVQNXQ15K851 
4.    Details of the transaction(s); section to be repeated 
       for (i) each type of instrument; (ii) each type of 
       transaction; (iii) each date; and (iv) each place 
       where transactions have been conducted 
 a.   Description of                               Oxford Biomedica plc Ordinary Shares 
       the financial                                of 50p each 
       instrument, type                             GB00BDFBVT43 
       of instrument 
       identification 
       code 
b.    Nature of the                                Purchase of ordinary shares 
       transaction 
c.    Currency                                     GBP - British Pound 
d.    Price(s) and volume(s)                             Price(s)               Volume(s) 
                                 GBP5.77                                         17,953 
 
e.          Aggregated information                 17,953 
              *    Aggregated volume                GBP5.76828385 
                                                    GBP103,558.00 
 
              *    Price 
 
 
              *    Aggregated total 
f.    Date of the transaction                      2019-09-12 
g.    Place of the transaction                     London Stock Exchange, Main Market (XLON) 
 

The issued share capital of the Group is 76,767,971 ordinary 50p shares.

-Ends-

 
 For further information, please contact: 
  Oxford Biomedica plc:                      Tel: +44 (0)1865 783 000 
   Natalie Walter, Company Secretary 
 

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector(R) ), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Santen, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 480 people. Further information is available at www.oxb.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

DSHUOVKRKRAKARR

(END) Dow Jones Newswires

September 13, 2019 05:53 ET (09:53 GMT)

1 Year Oxford Biomedica Chart

1 Year Oxford Biomedica Chart

1 Month Oxford Biomedica Chart

1 Month Oxford Biomedica Chart
Your Recent History
LSE
OXB
Oxford Bio..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20191023 13:41:06